Model 4965 Post-Approval Study

As part of the requirement to satisfy the PMA Conditions of Approval for the Medtronic Model
4965 CapSure Epi® Steroid-Eluting Unipolar Epicardial Pacing Lead, 50 adult subjects who were
≥19 years old at time of implant were followed for one-year post-implant.

Inclusion Criteria:

- Subjects or appropriate legal guardians provide written informed consent and/or
authorization for access to and use of health information, as required by an
institution's IRB/MEC/REB

AND one of the following (A, B, or C) must also apply:

A. Subjects indicated for implant or within six months post-implant of a Medtronic
market-released lead connected to a market-released IPG, ICD, or CRT Device. The Medtronic
lead must be used for a pacing, sensing, or defibrillation application.

B. Subjects who participated in a qualifying study of a Medtronic cardiac therapy product
and for whom:

- product is market-released

- complete implant and follow-up data, including product-related adverse events, are
available

- subject or appropriate legal guardian authorizes release of subject study data to SLS
C. Subjects implanted with Medtronic CapSure Epi Leads (model 4965 and 4968) at a
minimum of three pre-selected sites to retrospectively collect data for post approval
requirements. Post approval requirements indicate 50 adult subjects implanted with a
model 4965 and 100 subjects (pediatric and adult) implanted with a model 4968. The
study plans to enroll approximately 100 subjects with a model 4965 lead and
approximately 200 subjects with a model 4968 lead.

Note: Subjects currently active in the Chronic Lead Study or Tachyarrhythmia Chronic
Systems Study will continue in the follow-up phase of the SLS.

Exclusion Criteria:

- Subjects receiving an implant of a Medtronic lead at a non-participating center and
the implant data and current status cannot be confirmed within 30 days after implant

- Subjects who are, or will be inaccessible for follow-up at a SLS center

- Subjects implanted with a Medtronic cardiac therapy device whose predetermined
enrollment limit for that specific product has been exceeded

- Subjects with exclusion criteria required by local law (EMEA only)